股价一路上行之际，再鼎医药披露的年报，将投资者的热情推向高潮。然而，再鼎医药虽然实现了亏损的大幅收窄，但这并不意味着公司已经盈利，事实上，近七年再鼎医药已经巨亏23.42亿美元，从“买药上市”到“自研突围”，再鼎模式想要实现扭亏似乎仍有不短的路要走。再鼎医药给欣欣向荣的港股创新药板块添了一把火。3月27日晚间，再鼎医药发布2024年年报，公司实现总收入3.99亿美元，同比增长49.59%。亏损收窄...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.